(Q61365552)

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-4 prevents mortality from acute but not chronic murine peritonitis and induces an accelerated tumor necrosis factor-alpha response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Decreased mucosal interleukin-4 (IL-4) production in gut inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Inflammatory cytokines in cystic fibrosis lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Macrophage deactivation by interleukin 10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysacchari

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Regulation by anti-inflammatory cytokines (IL-4, IL-10, IL-13, TGFbeta)of interleukin-8 production by LPS- and/ or TNFalpha-activated human polymorphonuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-10 inhibits cytokine generation from mast cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Modified immunological status of anti-IL-10 treated mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Endogenous interleukin 10 prevents apoptosis in macrophages during Salmonella infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Apoptosis in human alveolar macrophages is induced by endotoxin and is modulated by cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-10 production during septicaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-10 regulation in normal subjects and patients with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Increased interleukin-10 messenger RNA expression in atopic allergy and asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-10-deficient mice develop chronic enterocolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Methylprednisolone differentially regulates IL-10 and tumour necrosis factor (TNF) production during murine endotoxaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Targeting TGF-beta for treatment of disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Transforming growth factor beta 1 regulation of macrophage activation depends on the triggering stimulus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Release of transforming growth factor-beta (TGF-beta) and fibronectin by alveolar macrophages in airway diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Elevated levels of circulating transforming growth factor-beta 1 in patients with the sepsis syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Cytokine regulation of human monocyte interleukin-1 (IL-1) production in vitro. Enhancement of IL-1 production by interferon (IFN) gamma, tumour necrosis factor-alpha, IL-2 and IL-1, and inhibition by IFN-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Endogenous interferon α/β produced by Kupffer cells inhibits interleukin-1, tumor necrosis factor α production and interleukin-2-induced activation of nonparenchymal liver cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Exogenous and endogenous type I interferons inhibit interferon-gamma-induced nitric oxide production and nitric oxide synthase expression in murine peritoneal macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alfa-2b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interferon-alpha prevents endotoxin-induced mortality in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-1 receptor antagonist reduces mortality from endotoxin shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-β

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

IL-10 and IL-4 synergize with TNF-α to induce IL-1ra production by human neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Protection by alpha 1-acid glycoprotein against tumor necrosis factor-induced lethality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Impaired immune and acute-phase responses in interleukin-6-deficient mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Defective inflammatory response in interleukin 6-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-4 and interleukin-10 increase endotoxin-stimulated human umbilical vein endothelial cell interleukin-8 release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Induction of interleukin-1 and interleukin-8 mRNAs and proteins by TGF beta 1 in rat lung alveolar epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Monocytes cultured in cytokine-defined environments differ from freshly isolated monocytes in their responses to IL-4 and IL-10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-10 (IL-10) inhibits the induction of nitric oxide synthase by interferon-gamma in murine macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-10 inhibits IgE-mediated nitric oxide synthase induction and cytokine synthesis in normal human keratinocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Induction of macrophage nitric oxide production by interferon-gamma and tumor necrosis factor-alpha is enhanced by interleukin-10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Mechanism of enhanced susceptibility to sepsis following hemorrhage. Interleukin-10 suppression of T-cell response is mediated by eicosanoid-induced interleukin-4 release.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Dysregulation of in vitro cytokine production by monocytes during sepsis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9

inferred from DOI database lookup

7 January 2021

based on heuristic

Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0020-2452%2897%2982541-9